End-of-day quote
Korea S.E.
23:00:00 02/05/2024 BST
|
5-day change
|
1st Jan Change
|
5,580
KRW
|
+0.54%
|
|
+3.72%
|
-28.00%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
146,253
|
70,835
|
310,488
|
216,446
|
165,128
|
118,431
|
Enterprise Value (EV)
1 |
143,620
|
50,066
|
278,429
|
124,955
|
71,561
|
66,917
|
P/E ratio
|
-2.2
x
|
-7.08
x
|
-6.92
x
|
6.89
x
|
6.73
x
|
-13.6
x
|
Yield
|
-
|
-
|
-
|
-
|
1.48%
|
-
|
Capitalization / Revenue
|
26.8
x
|
18.4
x
|
7.51
x
|
2.8
x
|
1.63
x
|
16.6
x
|
EV / Revenue
|
26.4
x
|
13
x
|
6.73
x
|
1.62
x
|
0.71
x
|
9.38
x
|
EV / EBITDA
|
-35.1
x
|
-7.77
x
|
11.9
x
|
3.45
x
|
2.5
x
|
-3.72
x
|
EV / FCF
|
-
|
27,483,985
x
|
-47,267,788
x
|
3,920,252
x
|
-28,742,142
x
|
-3,116,853
x
|
FCF Yield
|
-
|
0%
|
-0%
|
0%
|
-0%
|
-0%
|
Price to Book
|
9.5
x
|
2.91
x
|
4.92
x
|
2.15
x
|
1.17
x
|
1.05
x
|
Nbr of stocks (in thousands)
|
11,426
|
12,926
|
15,295
|
15,460
|
16,269
|
15,281
|
Reference price
2 |
12,800
|
5,480
|
20,300
|
14,000
|
10,150
|
7,750
|
Announcement Date
|
19/03/20
|
19/03/20
|
17/03/21
|
23/03/22
|
21/03/23
|
20/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
5,449
|
3,845
|
41,352
|
77,201
|
101,399
|
7,132
|
EBITDA
1 |
-4,090
|
-6,444
|
23,395
|
36,209
|
28,587
|
-17,975
|
EBIT
1 |
-4,603
|
-7,069
|
22,512
|
34,814
|
24,971
|
-22,758
|
Operating Margin
|
-84.48%
|
-183.85%
|
54.44%
|
45.09%
|
24.63%
|
-319.08%
|
Earnings before Tax (EBT)
1 |
-40,930
|
-9,562
|
-40,817
|
43,310
|
32,322
|
-18,722
|
Net income
1 |
-40,915
|
-9,561
|
-41,018
|
36,152
|
26,717
|
-17,238
|
Net margin
|
-750.91%
|
-248.66%
|
-99.19%
|
46.83%
|
26.35%
|
-241.69%
|
EPS
2 |
-5,807
|
-774.0
|
-2,935
|
2,033
|
1,509
|
-570.4
|
Free Cash Flow
|
-
|
1,822
|
-5,890
|
31,874
|
-2,490
|
-21,469
|
FCF margin
|
-
|
47.38%
|
-14.24%
|
41.29%
|
-2.46%
|
-301.02%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
88.03%
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
88.17%
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
150.0
|
-
|
Announcement Date
|
19/03/20
|
19/03/20
|
17/03/21
|
23/03/22
|
21/03/23
|
20/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
2,633
|
20,769
|
32,059
|
91,491
|
93,567
|
51,514
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
1,822
|
-5,890
|
31,874
|
-2,490
|
-21,469
|
ROE (net income / shareholders' equity)
|
-
|
-46.3%
|
-92.3%
|
41.8%
|
20.9%
|
-13.5%
|
ROA (Net income/ Total Assets)
|
-
|
-12.7%
|
23.9%
|
19.1%
|
9.49%
|
-9.28%
|
Assets
1 |
-
|
75,517
|
-171,824
|
189,426
|
281,485
|
185,719
|
Book Value Per Share
2 |
1,347
|
1,880
|
4,126
|
6,514
|
8,641
|
7,361
|
Cash Flow per Share
2 |
99.10
|
204.0
|
1,092
|
4,276
|
3,201
|
1,458
|
Capex
1 |
1,853
|
1,856
|
4,387
|
5,227
|
15,848
|
5,651
|
Capex / Sales
|
34%
|
48.27%
|
10.61%
|
6.77%
|
15.63%
|
79.23%
|
Announcement Date
|
19/03/20
|
19/03/20
|
17/03/21
|
23/03/22
|
21/03/23
|
20/03/24
|
|
1st Jan change
|
Capi.
|
---|
| -28.00% | 62.89M | | -1.89% | 12.56B | | -9.59% | 7.68B | | +21.82% | 5.18B | | -1.31% | 5.29B | | +0.02% | 4.57B | | -50.89% | 3.29B | | +6.42% | 2.6B | | -10.02% | 2.2B | | -8.29% | 1.79B |
Diagnostic & Testing Substances
|